Safe Fertility Group PCL

Safe Fertility Group PCL FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Safe Fertility Group PCL (SAFE.BK) as of Oct 25, 2026 is 112.81 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 84.02 % — a change of 34.27% (higher).

FCF Conversion

112.81 %

YoY

34.27%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Safe Fertility Group PCL is 2024 112.81 % . FCF Conversion Rate (FCF/EBITDA) of Safe Fertility Group PCL was 2023 84.02 % . It decreases by 34.27% higher compared to the previous year.

The Safe Fertility Group PCL FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2022
108.70 THB
Jan 1, 2023
84.02 THB
Jan 1, 2024
112.81 THB
The Safe Fertility Group PCL FCF Conversion history
YEARFCF ConversionYoY
112.81 %+34.27%
84.02 %-22.71%
108.70 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Safe Fertility Group PCL Stock analysis

What does Safe Fertility Group PCL do? Safe Fertility Group PCL operates in the medical assisted reproductive technology and medical laboratories sector in Thailand. The company provides fertility treatment centers and supports its services through subsidiaries like Next Generation Genomics Co., Ltd., which offers genetic diagnosis for embryos and fetuses, and Safe Wellness Company Limited, which delivers skin and beauty services. These subsidiaries serve customers from hospitals and obstetric clinics, enhancing the company's comprehensive healthcare offerings. The firm's revenue streams come from fertility treatments, genetic diagnostic services, and beauty services provided to medical institutions and clinics. Safe Fertility Group PCL's business model relies on its subsidiaries to expand service offerings, with Next Generation Genomics focusing on genetic testing and Safe Wellness targeting wellness and beauty needs. The company's primary clients are hospitals and obstetric clinics seeking specialized reproductive and genetic services. Revenue is generated through direct service provision at fertility centers and via partnerships with healthcare providers for genetic and beauty services. The company's core products include medical assisted reproductive technology services, genetic diagnosis for embryos and fetuses, and skin and beauty treatments. These are sold to hospitals and obstetric clinics as part of their healthcare service packages. Safe Fertility Group PCL's subsidiaries play a key role in delivering these services, ensuring a full spectrum of care from fertility treatment to post-treatment wellness solutions. Safe Fertility Group PCL is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Safe Fertility Group PCL stock

FCF Conversion Rate (FCF/EBITDA) of Safe Fertility Group PCL is 112.81 % in 2024.

FCF Conversion Rate (FCF/EBITDA) of Safe Fertility Group PCL changed from 84.02 % to 112.81 %, representing a 34.27% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Safe Fertility Group PCL since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Safe Fertility Group PCL with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Safe Fertility Group PCL

All Key Metrics — Safe Fertility Group PCL